GlassScriptPhysician profile
Bilkish Chunara
NPI 1003233370
$2,941.47
in general payments reported to CMS, 2019-2025
21 companies · $823 in 2025
The $823 reported for 2025 was more than what 82% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $227 · 2022: $544 · 2023: $305 · 2024: $1,043 · 2025: $823.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,171.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,170.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $399.70 | 2023-2025 | |
| Abbott Laboratories | $312.86 | 2022-2024 | Freestyle Libre 3 |
| Amgen INC. | $245.60 | 2025 | Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $233.25 | 2022-2025 | |
| Novo Nordisk INC | $171.38 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Hologic Sales and Service, LLC | $150.00 | 2025 | Aptima |
| Neurelis, INC. | $125.00 | 2024 | Valtoco |
| Sk Life Science, INC. | $124.10 | 2024 | Xcopri |
| Lexicon Pharmaceuticals, INC. | $121.81 | 2024 | Inpefa |
| Astrazeneca Pharmaceuticals LP | $120.16 | 2021 | |
| Biotissue Holdings INC. | $116.34 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $111.17 | 2022 | |
| Genentech USA, INC. | $106.57 | 2021 | |
| Sumitomo Pharma America, INC. | $104.69 | 2023 | Gemtesa |
| Exeltis, USA INC. | $103.35 | 2025 | Slynd, Twirla |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $100.04 | 2022 | |
| Kyowa Kirin, INC. | $95.72 | 2024 | Crysvita |
| Sanofi-Aventis U.S. LLC | $81.88 | 2024 | |
| Coloplast Corp | $67.87 | 2024 | |
| Xeris Pharmaceuticals, INC. | $27.88 | 2025 | Gvoke Hypopen |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $22.10 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bilkish Chunara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.